Ozempic and Wegovy have ushered in a rapidly expanding field of obesity drugs, with pharma firms big and small eager to cash in on the massive weight loss drug windfall Other drug candidates in mid-stage development for obesity include Viking Therapeutics VK2735, Structure Therapeutics GSBR-1290 and Altimmunes pemvidutide, Pfizers danuglipron, Amgens AMG133, also known as MariTide, and Roches CT-996 and CT-388
Caffeine disrupts vitamin D receptor function in follicular cells, potentially reducing the vitamins effectiveness even with adequate sun exposure and production
YTHDF1 targets the chemotherapy response by suppressing NOTCH1-induced stemness in colorectal cancer
Folic acid supplementation improves glycemic control for diabetes prevention and management: a systematic review and dose-response meta-analysis of randomized controlled trials
Like with methacholine, the extra methyl side group in bethanechol results in selectivity for muscarinic vs nicotinic receptors, and contributes to resistance to metabolism by cholinesterases
Nausea during the first 34 weeks is a normal adaptation response, not a sign that tirzepatide is ineffective or unsafe
